Latest Regulatory Filings News

Papyrus Australia has secured a key milestone under its TBS Mining Contract by executing a board production deal with a Vietnam manufacturer, while raising $325,000 to support commercial scale-up and facility establishment.

AnteoTech has locked in an underwriting deal to guarantee up to $7.5 million from the exercise of listed options, potentially raising as much as $10 million before costs.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

DGR Global lodged a key director interest notice 14 days late due to an administrative slip, prompting an ASX compliance query. The company has outlined its existing governance measures and pledged refresher training to tighten disclosure controls.

Bio-Gene Technology has raised A$3.21 million to complete critical safety studies for its novel insecticide Flavocide and ramp up production of its natural insecticide Qcide, advancing its path to commercialisation in multiple global markets.

Red Sky Energy has closed a fully underwritten rights issue, securing $2.46 million from shareholders and relying on underwriting to cover a $1.69 million shortfall. The new shares will be issued today, supporting the company’s ongoing funding needs.

Mt Malcolm Mines (ASX:M2M) is gearing up for a major drilling campaign at its Calypso Gold Prospect, aiming to convert a substantial Exploration Target into a JORC-compliant Mineral Resource. The program follows high-grade discoveries at the newly identified T3 Constance Lode and historical multi-lode mineralisation.

Vitrafy Life Sciences has achieved a major validation milestone with US Army-backed Phase II results showing its no-wash platelet cryopreservation protocol delivers 94% post-thaw recovery, outperforming existing standards and advancing FDA registration plans.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

OncoSil Medical has clinched TGA approval for its OncoSil™ device, the first Class III medical device targeting pancreatic tumours in Australia, paving the way for local commercialisation and enhanced patient access.

James Hardie Industries saw a 25% sales increase in FY26 driven by the AZEK acquisition but reported a 75% net income decline amid acquisition costs and margin pressures. The company expects synergy gains and adjusted EBITDA growth in FY27.

Lumos Diagnostics advances US commercial rollout of FebriDx with positive reimbursement data and expanded urgent care adoption ahead of the 2027/28 flu season.